ES2927212T3 - Análogos de dioxano de uridina para el tratamiento de cáncer - Google Patents

Análogos de dioxano de uridina para el tratamiento de cáncer Download PDF

Info

Publication number
ES2927212T3
ES2927212T3 ES19177824T ES19177824T ES2927212T3 ES 2927212 T3 ES2927212 T3 ES 2927212T3 ES 19177824 T ES19177824 T ES 19177824T ES 19177824 T ES19177824 T ES 19177824T ES 2927212 T3 ES2927212 T3 ES 2927212T3
Authority
ES
Spain
Prior art keywords
mmol
alkyl
compound
mixture
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19177824T
Other languages
English (en)
Spanish (es)
Inventor
Richard Bethel
Anders Eneroth
Björn Klasson
Fredrik ÖBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir AB filed Critical Medivir AB
Application granted granted Critical
Publication of ES2927212T3 publication Critical patent/ES2927212T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES19177824T 2014-08-25 2015-08-24 Análogos de dioxano de uridina para el tratamiento de cáncer Active ES2927212T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1450983 2014-08-25
SE1550858 2015-06-22

Publications (1)

Publication Number Publication Date
ES2927212T3 true ES2927212T3 (es) 2022-11-03

Family

ID=54014804

Family Applications (2)

Application Number Title Priority Date Filing Date
ES19177824T Active ES2927212T3 (es) 2014-08-25 2015-08-24 Análogos de dioxano de uridina para el tratamiento de cáncer
ES15756888T Active ES2796089T3 (es) 2014-08-25 2015-08-24 Análogos de dioxano de uridina para el tratamiento de cáncer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15756888T Active ES2796089T3 (es) 2014-08-25 2015-08-24 Análogos de dioxano de uridina para el tratamiento de cáncer

Country Status (24)

Country Link
US (7) US10144750B2 (OSRAM)
EP (2) EP3186244B1 (OSRAM)
JP (2) JP6663424B2 (OSRAM)
KR (2) KR102398714B1 (OSRAM)
CN (4) CN111269264A (OSRAM)
AU (2) AU2015308988C1 (OSRAM)
BR (1) BR112017003898B1 (OSRAM)
CA (2) CA2956251C (OSRAM)
CY (1) CY1122945T1 (OSRAM)
DK (2) DK3186244T3 (OSRAM)
EA (2) EA033300B1 (OSRAM)
ES (2) ES2927212T3 (OSRAM)
HR (1) HRP20201023T1 (OSRAM)
HU (2) HUE050705T2 (OSRAM)
IL (2) IL250344B (OSRAM)
MX (1) MX369649B (OSRAM)
MY (2) MY188089A (OSRAM)
NZ (2) NZ729118A (OSRAM)
PH (2) PH12017500184B1 (OSRAM)
PL (2) PL3186244T3 (OSRAM)
PT (2) PT3186244T (OSRAM)
SG (3) SG10201911558UA (OSRAM)
WO (1) WO2016030335A1 (OSRAM)
ZA (1) ZA201802864B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201911558UA (en) * 2014-08-25 2020-01-30 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
PT3386998T (pt) * 2015-12-11 2021-11-30 NuCana plc Síntese diastereosseletiva de derivados fosfato e do pró-fármaco gemcitabina nuc-10311
PL3423061T3 (pl) * 2016-03-02 2024-12-16 Medivir Aktiebolag Leczenie skojarzone sorafenibem lub regorafenibem i amidofosforanowym prolekiem troksacytabiny
CN106432328B (zh) * 2016-09-14 2019-03-22 江苏福瑞生物医药有限公司 一种索非布韦中间体的制备方法
AU2017361855A1 (en) * 2016-11-18 2019-05-30 Neurovive Pharmaceutical Ab Liver prodrugs of mitochondrial proton ionophores
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
CN110964057B (zh) * 2019-12-25 2022-05-06 东南大学 一种利用微流体反应装置制备索非布韦中间体的方法
CN113402546A (zh) * 2020-03-17 2021-09-17 浙江四维医药科技有限公司 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
US20240024342A1 (en) * 2020-04-15 2024-01-25 Medivir Ab Miv-818/lenvatinib combination therapy for liver cancer
CN113754692B (zh) * 2020-06-03 2022-06-10 上海交通大学 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN114685558A (zh) * 2020-12-28 2022-07-01 尚科生物医药（上海）有限公司 一种瑞德西韦中间体的制备方法
CN114249764A (zh) * 2021-11-10 2022-03-29 宁波大学 一种磷酰胺酯类前药的中间体及其制备方法与应用
WO2025155547A1 (en) * 2024-01-17 2025-07-24 University Of Georgia Research Foundation, Inc. An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6022876A (en) 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
WO2002030922A2 (en) * 2000-10-13 2002-04-18 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2007106450A2 (en) * 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
AU2007293377A1 (en) * 2006-09-01 2008-03-13 University Of Georgia Research Foundation, Inc. L- OddC prodrugs for cancer
PL216525B1 (pl) 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
BR112016011949A8 (pt) * 2013-11-27 2020-04-28 Idenix Pharmaceuticals Llc composto, composição farmacêutica, e, uso dos mesmos”
SG10201911558UA (en) * 2014-08-25 2020-01-30 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer

Also Published As

Publication number Publication date
JP6663424B2 (ja) 2020-03-11
AU2018201980A1 (en) 2018-04-12
EA031106B1 (ru) 2018-11-30
MY198325A (en) 2023-08-24
IL250344B (en) 2020-01-30
EP3572410A1 (en) 2019-11-27
CA3128645A1 (en) 2016-03-03
US10336780B2 (en) 2019-07-02
US20170267705A1 (en) 2017-09-21
DK3572410T3 (da) 2022-08-29
PL3186244T3 (pl) 2020-11-16
SG10202001117YA (en) 2020-04-29
US20190389890A1 (en) 2019-12-26
US10822360B2 (en) 2020-11-03
CA3128645C (en) 2023-06-27
CA2956251C (en) 2022-10-25
JP6905609B2 (ja) 2021-07-21
EA033300B1 (ru) 2019-09-30
SG10201911558UA (en) 2020-01-30
PT3186244T (pt) 2020-05-29
HUE059640T2 (hu) 2022-12-28
US20230117570A1 (en) 2023-04-20
AU2015308988C1 (en) 2018-09-06
KR20200035482A (ko) 2020-04-03
US11447511B2 (en) 2022-09-20
EP3186244B1 (en) 2020-04-22
EP3186244A1 (en) 2017-07-05
CA2956251A1 (en) 2016-03-03
SG11201701172SA (en) 2017-03-30
EA201790328A1 (ru) 2017-08-31
US10654877B2 (en) 2020-05-19
DK3186244T3 (da) 2020-07-13
CN107074826B (zh) 2020-05-22
AU2015308988B2 (en) 2018-04-26
HRP20201023T1 (hr) 2020-10-16
JP2017526677A (ja) 2017-09-14
NZ762628A (en) 2023-04-28
BR112017003898B1 (pt) 2022-10-18
CN110804072A (zh) 2020-02-18
ZA201802864B (en) 2019-07-31
EA201890648A3 (ru) 2019-02-28
AU2015308988A1 (en) 2017-02-23
BR112017003898A2 (pt) 2017-12-05
MX2017002328A (es) 2017-05-22
PH12017500184A1 (en) 2017-06-28
CY1122945T1 (el) 2021-10-29
EA201890648A2 (ru) 2018-08-31
CN110790789A (zh) 2020-02-14
CN110804072B (zh) 2023-05-12
MX369649B (es) 2019-11-15
IL266766A (en) 2019-07-31
PL3572410T3 (pl) 2022-10-03
HUE050705T2 (hu) 2020-12-28
AU2018201980B2 (en) 2019-05-16
CN110790789B (zh) 2023-05-12
KR20170046736A (ko) 2017-05-02
ES2796089T3 (es) 2020-11-25
US20200239502A1 (en) 2020-07-30
MY188089A (en) 2021-11-17
NZ729118A (en) 2022-02-25
US20230382931A1 (en) 2023-11-30
CN107074826A (zh) 2017-08-18
PT3572410T (pt) 2022-09-15
KR102398714B1 (ko) 2022-05-17
US20190100541A1 (en) 2019-04-04
IL266766B (en) 2020-05-31
KR102396905B1 (ko) 2022-05-13
JP2020090535A (ja) 2020-06-11
US10144750B2 (en) 2018-12-04
PH12019501919A1 (en) 2020-09-14
IL250344A0 (en) 2017-03-30
EP3572410B1 (en) 2022-07-20
US20210054008A1 (en) 2021-02-25
CN111269264A (zh) 2020-06-12
PH12017500184B1 (en) 2017-06-28
WO2016030335A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
ES2927212T3 (es) Análogos de dioxano de uridina para el tratamiento de cáncer
HK40014376B (en) Dioxolane analogues of uridine for the treatment of cancer
HK40014377B (en) Dioxolane analogues of uridine for the treatment of cancer
HK40011623B (en) Dioxolane analogues of uridine for the treatment of cancer
HK40011623A (en) Dioxolane analogues of uridine for the treatment of cancer
TWI695841B (zh) 治療癌症之前藥
HK1240591A1 (en) Dioxolane analogues of uridine for the treatment of cancer
HK1240591B (en) Dioxolane analogues of uridine for the treatment of cancer
HK1235405A1 (en) Dioxolane analogues of uridine for the treatment of cancer